Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REC 0545

Drug Profile

REC 0545

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Assistance Publique Hopitaux de Paris; Recordati
  • Class Amino acids
  • Mechanism of Action Serotonin 1A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Maple syrup urine disease
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Maple syrup urine disease
  • Discontinued Genitourinary disorders; Overactive bladder

Most Recent Events

  • 05 Nov 2018 REC 0545 receives Orphan Drug status for Maple syrup urine disease in European Union
  • 01 Mar 2018 Recordati and Assistance Publique Hopitaux de Paris plans a clinical trial for Maple syrup urine disease (Recordati pipeline, February 2018)
  • 31 Dec 2007 Discontinued - Phase-II for Overactive bladder in Europe (unspecified route)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top